1
Pouwels, X. G. L. V., Geurts, S. M. E., Ramaekers, B. L. T., Erdkamp, F., Vriens, B. E. P. J., Aaldering, K. N. A., van de Wouw, A. J., Dercksen, M. W., Smilde, T. J., Peters, N. A. J. B., Riel, J. M. van, Pepels, M. J., Heijnen-Mommers, J., Joore, M. A., Tjan-Heijnen, V. C. G., de Boer, M.
Veröffentlicht in: Pouwels , X G L V , Geurts , S M E , Ramaekers , B L T , Erdkamp , F , Vriens , B E P J , Aaldering , K N A , van de Wouw , A J , Dercksen , M W , Smilde , T J , Peters , N A J B , Riel , J M V , Pepels , M J , Heijnen-Mommers , J , Joore , M A , Tjan-Heijnen , V C G & de Boer , M 2020 , ' The relative effectiveness of eribulin for advanced breast cancer treatment : a study of the southeast Netherlands advanced breast cancer registry ' , Acta Oncologica , vol. 59 , no. 1 , pp. 82-89 . https://doi.org/10.1080/0284186X.2019.1670356;
2020
Veröffentlicht in: Pouwels , X G L V , Geurts , S M E , Ramaekers , B L T , Erdkamp , F , Vriens , B E P J , Aaldering , K N A , van de Wouw , A J , Dercksen , M W , Smilde , T J , Peters , N A J B , Riel , J M V , Pepels , M J , Heijnen-Mommers , J , Joore , M A , Tjan-Heijnen , V C G & de Boer , M 2020 , ' The relative effectiveness of eribulin for advanced breast cancer treatment : a study of the southeast Netherlands advanced breast cancer registry ' , Acta Oncologica , vol. 59 , no. 1 , pp. 82-89 . https://doi.org/10.1080/0284186X.2019.1670356;
2020
2
Wagner, Anna Dorothea, Grabsch, Heike, Mauer, Murielle, Marreaud, Sandrine, Caballero, Carmela, Thuss-Patience, Peter, Mueller, Lothar, Elme, Annelie, Moehler, Markus Hermann, Martens, Uwe, Kang, Yoon-Koo, Rha, Sun Young, Cats, Annemieke, Tokunaga, Masanori, Lordick, Florian
Veröffentlicht in: Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group ' , BMC Cancer , vol. 19 , 494 . https://doi.org/10.1186/s12885-019-5675-4;
2019
Veröffentlicht in: Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group ' , BMC Cancer , vol. 19 , 494 . https://doi.org/10.1186/s12885-019-5675-4;
2019